Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MDM2 and prognosis.

Kenan Onel1, Carlos Cordon-Cardo

  • 1Division of Molecular Pathology, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

Molecular Cancer Research : MCR
|February 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer's disease.

Nature communications·2026
Same author

Development of an adult neurofibromatosis clinic in the comprehensive cancer center setting and descriptive analysis of the first 100 patients with neurofibromatosis type 1.

Orphanet journal of rare diseases·2026
Same author

Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.

JCO precision oncology·2026
Same author

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Cancer discovery·2026
Same author

Author Correction: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Nature genetics·2026
Same author

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Blood·2026
Same journal

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same journal

Comprehensive multi-omic profiling of desmoplastic small round cell tumors identifies targetable pathways with therapeutic opportunities.

Molecular cancer research : MCR·2026
Same journal

CELF2 is a tumor suppressor that modulates SLC7A11 and promotes ferroptosis in stomach adenocarcinoma.

Molecular cancer research : MCR·2026
Same journal

MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer.

Molecular cancer research : MCR·2026
Same journal

Ceramide-induced endoplasmic reticulum stress reveals a targetable vulnerability in endocrine therapy-resistant breast cancer.

Molecular cancer research : MCR·2026
Same journal

Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells.

Molecular cancer research : MCR·2026
See all related articles

The p53-MDM2 feedback loop is crucial for preventing cancer. While MDM2 overexpression is common, its role as a cancer biomarker is complex and requires further research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p53 tumor suppressor pathway is vital for genomic stability and cancer prevention.
  • Intracellular p53 levels are regulated by a feedback loop involving p53 and MDM2.
  • Disruption of the p53-MDM2 loop, via p53 mutation or MDM2 overexpression, is often linked to cancer.

Purpose of the Study:

  • To review the predictive significance of MDM2 expression in various tumor types.
  • To explore the diverse mechanisms driving MDM2 overexpression in cancer.
  • To understand the complexities of the p53-MDM2 loop for developing relevant biomarkers.

Main Methods:

  • Review of existing data on MDM2 expression and patient outcomes across different cancers.
  • Analysis of studies investigating mechanisms of MDM2 overexpression.

Related Experiment Videos

  • Examination of the biological interactions and regulatory pathways involving p53 and MDM2.

    • Main Results:

    • MDM2 overexpression is frequent in cancer but has controversial prognostic value, acting as both a positive and negative predictor.
    • Mechanisms of MDM2 overexpression vary significantly among different tumor types.
    • The predictive significance of MDM2 is complicated by the intricate regulatory network of the p53-MDM2 loop.

    Conclusions:

    • The role of MDM2 as a cancer biomarker is not straightforward due to biological complexities.
    • Further research is needed to elucidate protein interactions, post-translational modifications, and regulatory deregulations.
    • Understanding these fundamental mechanisms is essential for identifying reliable predictive factors in cancer.